Hepatitis C Virus Infection Completed Phase 2 Trials for Daclatasvir (DB09102)

Indication	Status	Phase
DBCOND0033268 (Hepatitis C Virus Infection)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04019717	Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection	Treatment	AT-527 (DB16451) Daclatasvir (DB09102)
NCT01428063	Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials	Treatment	Asunaprevir (DB11586) Daclatasvir (DB09102) Peginterferon alfa-2a (DB00008) Ribavirin (DB00811)